The concept of company mission statements and their relevance are as polarizing a debate as any in the annals of management science. Some argue that a company's mission gives its purpose and establishes a framework for formulating a corporate strategy.
For decades, business users were able to analyze small sets of data independently using off-the-shelf tools like Microsoft Excel. Business users and technical non-IT personnel were able to perform a variety of tasks to extract value
Business Intelligence (BI) represents the collection of tools and technologies used to transform raw data into useful insights. BI and related analytics is one of the fastest growing industries with Gartner estimating the market to grow to $22.8bn by 20201.
On July 11 2016, President Obama became the first sitting president to publish an article in JAMA, the distinguished Journal of the American Medical Association. Even though...
Market access teams perform the critical task of articulating a drug’s value proposition to key payer decision-makers. Historically, that has meant MSLs, payer marketers, HEOR professionals...
MedPAC is going full Bulworth! Last month, the pharma and physician communities reacted with a collective gasp when MedPAC announced...
The Internets were ablaze earlier this week as Reuters broke the news that Anthem is looking for a way to end their long-term pharmacy benefit agreement with Express Scripts (ESI). Given the strategic importance of the Anthem business to Express Scripts (14% of ESI revenue), this was for once, a development with implications to match the headlines.
Pay-for-Performance (P4P) contracts have long been thought of as an effective way to address the disconnect between high drug prices and sub-optimal patient outcomes.
This is a follow-up to our last post about the affordability of specialty drugs within the Medicare Part D population. First, a quick review:
- Nearly half of Medicare recipients have annual incomes less than $24,150 and a full quarter of the recipients have annual incomes lower than $14,350
Since its inception, Medicare Part D has been a boon to seniors with a 2015 Medicare Today national survey showing that 89% of seniors are satisfied with their Part D drug coverage. In the same survey, 71% of seniors say they derive a great deal of peace of mind from their prescription drug coverage.
Express Scripts just fired the next shot across the bow in its much-publicized quest to control prescription drug costs. Beginning 2016, ESI is launching the SafeGuardRx℠ program, marketed as a “collection of novel solutions that will transform the pharmacy benefi
The last few weeks have seen a drip-drip-drip of news headlines about the rising prescription drug costs in the US. The New York Times just reported that federal prosecutors are investigating Valeant pharma for drug pricing practices.
Anthem’s recently proposed purchase of Cigna is expected to create the largest health insurance company in the US. If the transaction goes through, it will cap a dramatic episode in the continuing consolidation of the payer market.
Even the most ardent advocate for a single-payer system in the US would not have seen this convoluted path to get there: the rapid consolidation of the health insurance industry. Just in the last few weeks, there has been news about three major potential acquisitions: Aetna-Humana, Wellpoint-Cigna, and Centene-HealthNet.
Any moment now, the supreme court will rule on a case that challenges the legality of subsidies granted to eligible low and middle-income populations buying insurance through the federal health exchange. The Kaiser Family Foundation’s analysis of the case’s impact paints a stark picture of what’s at stake.
Research has shown that a 1% loss in net price can lead to a >5% decrease in operating profits. With the ever-increasing payer pressure for higher rebates, price protection, and other forms of concessions managed markets teams need to adopt best practices to minimize revenue leakage from unintended contracting events.
At Stotle, we often work with brands that have a large number of managed care contracts. These brands invest substantial Gross-To-Net dollars to secure the appropriate formulary access.
When contracts are signed, there is an expectation that the account teams will generate sufficient pull-through to justify the investment.
The continuing consolidation of the PBM business has led to two things:
- PBM purchasing power has grown dramatically
- Managed markets teams are having harder time assessing business performance